A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia
Jerard Ross1, David Brough, Rosemary M Gibson
1Faculty of Life Sciences, Michael Smith Building, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
Abstract:
Numerous preclinical studies have reported neuroprotective effects of new agents in animal studies. None of these agents has yet translated into a successful clinical trial and therefore to a new therapy. There are many possible reasons for this failure, including poor design of clinical trials, mismatch between preclinical and clinical protocols, and insufficient preclinical data. The enzyme caspase-1 has been implicated in neuronal death. Deletion of the caspase-1 gene, or administration of partially selective inhibitors, reduces neuronal injury induced by cerebral ischemia in rodents. We report here, for the first time, that VRT-018858, the non-peptide, active metabolite of the selective caspase-1 inhibitor pro-drug, pralnacasan, markedly reduced ischemic injury in rats. VRT-018858 was neuroprotective when delivered at 1 and 3h (42% and 58% neuroprotection, respectively) but not 6h after injury, and protection was sustained 7 days after the induction of ischemia (66% neuroprotection). These data confirm caspase-1 as an important target for intervention in acute CNS injury, and propose a new class of caspase-1 inhibitors as highly effective neuroprotective agents.
Insights
New research shows VRT-018858, a caspase-1 inhibitor, significantly reduces brain damage from ischemic stroke in rats. This finding highlights caspase-1 as a key target for developing effective neuroprotective therapies for acute central nervous system injuries.
Area of Science:
- Neuroscience
- Pharmacology
- Ischemic Stroke Research
Background:
- Preclinical studies often fail to translate into clinical neuroprotective therapies.
- Caspine-1 enzyme plays a role in neuronal death following ischemic events.
- Existing caspase-1 inhibitors have shown promise in rodent models of cerebral ischemia.
Purpose of the Study:
- To evaluate the neuroprotective potential of VRT-018858, a novel non-peptide caspase-1 inhibitor.
- To determine the efficacy and timing of VRT-018858 administration in reducing ischemic brain injury.
- To confirm caspase-1 as a viable therapeutic target for acute central nervous system (CNS) injury.
Main Methods:
- Administration of VRT-018858 at varying time points (1, 3, and 6 hours) post-ischemic injury induction in a rat model.
- Quantification of neuroprotection and assessment of injury severity.
- Long-term evaluation of neuroprotective effects up to 7 days after ischemia.
Main Results:
- VRT-018858 demonstrated significant neuroprotection when administered 1 and 3 hours after ischemic injury, with 42% and 58% reduction in injury, respectively.
- Neuroprotection was not observed when VRT-018858 was administered 6 hours post-injury.
- Sustained neuroprotection was evident at 7 days, showing a 66% reduction in ischemic injury.
Conclusions:
- Caspine-1 is a critical molecular target for mitigating neuronal damage in acute CNS injuries.
- VRT-018858, a selective caspase-1 inhibitor, represents a promising new class of neuroprotective agents.
- The timing of intervention is crucial for maximizing the therapeutic benefits of caspase-1 inhibitors in ischemic stroke.
